Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386368 · ClinicalTrials.gov registry record · Phase 4
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT05386368 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 1 participants.
The verdict
NCT05386368, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
To determine whether following Carbon dioxide (CO2) laser treatment, application of autologous cell suspension obtained via enzymatic and mechanical preparation will reduce negative side effects from CO2 laser and decrease the time of healing following treatment.
Interventions
- DRUG ReCell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05386368
The ClinicalTrials.gov registry entry for NCT05386368 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ReCell is the first listed.
NCT05386368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05386368 about?
NCT05386368 is a clinical study titled "RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients". To determine whether following Carbon dioxide (CO2) laser treatment, application of autologous cell suspension obtained via enzymatic and mechanical preparation will reduce negative side effects from CO2 laser and decrease the time of healing following treatment.
What is the current status of trial NCT05386368?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2023-03-22. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05386368?
The interventions under investigation include: ReCell (DRUG).
Who is sponsoring clinical trial NCT05386368?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.